Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company

VIVA Biotech Expands Global Footprint with New Boston Branch

Fineline Cube Dec 12, 2024

China-based Contract Research Organization (CRO) VIVA Biotech (HKG: 1873) has announced the inauguration of its...

Company Deals

Siemens Healthineers AG Acquires Advanced Accelerator Applications to Boost PETNET Solutions

Fineline Cube Dec 12, 2024

Germany-based Siemens Healthineers AG (ETR: SHL) has announced the completion of its acquisition of Advanced...

Company Deals

Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments

Fineline Cube Dec 12, 2024

Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and...

Company Deals

MDHC Life Technologies Secures Series C++ Funding to Boost Consumer Healthcare and Life Sciences

Fineline Cube Dec 12, 2024

China-based Contract Development Manufacturing Organization (CDMO) MDHC Life Technologies (Kunshan) Co.,Ltd has reportedly raised hundreds...

Company

Bayer AG’s Shanghai Co.Lab to Host Epigenic Therapeutics and Peers for CGT Innovation

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech...

Company Drug

AstraZeneca’s Lynparza Shows Sustained Improvements in OlympiA Phase III Study

Fineline Cube Dec 12, 2024

UK pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has updated data from the Phase III OlympiA...

Company Drug

Sanofi Receives FDA Fast-Track Designation for Influenza and COVID-19 Combo Vaccine Candidates

Fineline Cube Dec 12, 2024

Sanofi (NASDAQ: SNY) has announced that it has received Fast-Track Designations from the US Food...

Company Deals

Youjia Biomedical and Livzon Pharmaceutical Group Ink Licensing Deal for siRNA Drug

Fineline Cube Dec 12, 2024

China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd. has signed a licensing agreement with compatriot firm...

Company Deals

Bayer AG to Acquire HiDoc Technologies and Launch Digital Health App Cara Care

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced plans to acquire HiDoc Technologies GmbH in the...

Company Drug

Eli Lilly’s Imlunestrant Reduces Disease Progression in ER+/HER2- Advanced Breast Cancer: EMBER-3 Study

Fineline Cube Dec 12, 2024

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has published results from the Phase...

Policy / Regulatory

Shanghai Unveils Action Plan and Fund for Biopharma M&A Activities

Fineline Cube Dec 11, 2024

The Shanghai Municipal People’s Government has released the “Action Plan for Supporting Mergers and Acquisitions...

Company Deals

Fresenius Kabi Partners with Ori Biotech to Integrate IRO Platform with Cell Processing Systems

Fineline Cube Dec 11, 2024

Germany-based Fresenius Kabi, a leading name in healthcare, has struck an accord with Ori Biotech...

Company Drug

Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024

Fineline Cube Dec 11, 2024

Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) have jointly presented preliminary data...

Company Deals

GSK Enters Multi-Program Partnerships with Relation Therapeutics for Fibrotic Diseases and Osteoarthritis

Fineline Cube Dec 11, 2024

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has formed two multi-program strategic partnerships with compatriot...

Company Drug

Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024

Fineline Cube Dec 11, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE...

Company Drug

Legend Biotech’s Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial

Fineline Cube Dec 11, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) has released new data on minimal residual disease (MRD)...

Company Drug

Huadong Medicine’s Arcalyst Receives NMPA Approval for Recurrent Pericarditis Treatment

Fineline Cube Dec 11, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving another indication approval from the...

Company Drug

IMEIK Technology Receives NMPA Approval for Recombinant Human Hyaluronidase Clinical Study

Fineline Cube Dec 11, 2024

China-based IMEIK Technology Development Co., Ltd (SHE: 300896) has announced receiving approval from the National...

Company Drug

Patronus Biotech’s RSV Vaccine LYB005 Receives NMPA Approval for Clinical Study

Fineline Cube Dec 11, 2024

Guangzhou Patronus Biotech Co., Ltd., a vaccine start-up specializing in respiratory and infectious diseases, has...

Company Drug

Shanghai Pharmaceuticals’ SRD4610 Receives FDA Orphan Drug Designation for ALS Treatment

Fineline Cube Dec 11, 2024

China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that the US Food and...

Posts pagination

1 … 301 302 303 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.